Enveric Biosciences EBIT

Enveric Biosciences (ENVB) currently reports a EBIT of $-8.7M as of June 2026. That compares with $-10M in the prior-year period — up 12.4% year over year. That is below the Technology sector average of $13T. Use the charts on this page to explore Enveric Biosciences's EBIT history and peer comparisons.

Enveric Biosciences's EBIT increased from $-10M to $-8.7M — a 12.4% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Enveric Biosciences's EBIT of $-8.7M is lower than the Technology sector average of $13T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Enveric Biosciences reported $-8.7M in EBIT as of June 2026. That compares with $-10M in the prior-year period — up 12.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-8.7M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Technology average is $13T. From there, open related valuation or income-statement pages for Enveric Biosciences, and consider following ENVB for alerts when major investors trade the stock.